All In Biotech

Drug Trial Radar · NCT07219459

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Mar 19, 2026

Primary completion

Sep 2029

Study completion Sep 2031

Sponsor

Lead sponsor
CatalYm GmbHIndustry
Sponsor type
Industry
First posted
Oct 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable or metastatic HCC and compensated liver function (Child-Pugh A) after failure of 1L treatment that included an anti-PD-(L)1 compound. The trial consists of 2 Parts: a non-randomized Safety-run-in part (Part 1) and the subsequent randomized part (Part 2) with 2 treatment arms (A and B). Randomization of participants into Treatment Arm A and B will continue until 40 efficacy-evaluable participants are enrolled into each Treatment Arm.

Conditions

  • Unresectable or Metastatic Hepatocellular Carcinoma
  • Child-Pugh A Hepatocellular Carcinoma
  • Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

Interventions

  • Visugromab RDE (recommended dose for expansion)Biological

    Participants receive visugromab (RDE) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments

  • NivolumabBiological

    Participants receive Nivolumab 360mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion

  • LenvatinibDrug

    Participants receive Lenvatinib per os (PO) once daily according to body weight (\> 60kg: 12mg; \< 60kg: 8mg)

  • Placebo Saline InfusionOther

    Saline (0.9%NaCl) intravenous (2x IV) on Day 1 of every 21-day cycle every 3 weeks (Q3W) for up to 35 treatments

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: up to 36 months

Locations

29 sites in 7 countries. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UC Irvine Health. Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California · Recruiting

  • Peidmont Healthcare, Inc

    Atlanta, Georgia · Recruiting

  • OSF St. Francis Medical Center

    Peoria, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Montpellier University Hospital Center - Saint Eloi Hospital

    Montpellier, France · Recruiting

  • Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque

    Pessac, France · Recruiting

  • Poitiers University Hospital Center - Miletrie Hospital

    Poitiers, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität

    Frankfurt, Germany · Recruiting

  • Hannover Medical School

    Hanover, Lower Saxony, Germany · Recruiting

  • University Hospital Cologne, Clinic of Gastroenterology and Hepatology

    Cologne, North Rhine-Westphalia, Germany · Recruiting

  • University Medical Center of Johannes Gutenberg University Mainz

    Mainz, Rhineland-Palatinate, Germany · Recruiting

  • Polyclinic S. Orsola-Malpighi

    Bologna, Italy · Recruiting

  • Ospedale San Raffale, IRCCS

    Milan, Italy · Recruiting

  • Asst Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Recruiting

  • Ospedale S.Maria delle Croci

    Ravenna, Italy · Recruiting

  • University Hospital Miguel Servet

    Zaragoza, Aragon, Spain · Recruiting

  • Catalan Institute of Oncology, Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

  • Hospital Clinic of Barcelona

    Barcelona, Catalonia, Spain · Recruiting

  • University Clinic of Navarra - Pamplona

    Pamplona, Chartered Community of Navarra, Spain · Recruiting

  • University Hospital Ramon y Cajal

    Madrid, Madrid, Spain · Recruiting

  • Chia-Yi Christian Hospital

    Chiayi City, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • King's College Hospital

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.